03 November 2003
The use of corticosteroids versus other treatments for Graves’ ophthalmopathy: A quantitative evaluation
Sheikha Abalkhail, Suhail A.R. Doi, Kamal A.S. Al-ShoumerMed Sci Monit 2003; 9(11): CR477-483 :: ID: 13371
Abstract
Background:The purpose of the present study was to evaluate the efficacy of corticosteroids in the treatment of Graves’ ophthalmopathy in comparison to other treatment modalities.Material/Methods:15 studies were identified but only 14 were included in the final analysis, 5 cohort and 9 randomized. A total of 813 patients were included in this quantitative review.Results:The relative risk with oral corticosteroid treatment (OCS) alone vs. other treatment could not be pooled, as the studies were heterogeneous and the RR was dependent on risk of failure in the control group. In the two studies that reported head-on comparison between OCS and radiotherapy, no clinically significant difference was found. However, the combination of OCS and radiotherapy was markedly more effective than either modality alone (pooled RRR 70%). The number of patients who should be treated with the combination of CS and radiotherapy to prevent one more failure was between 3 to 8. Evidence from the studies suggest that intravenous corticosteroid's IVCSs used alone have similar or greater efficacy than the combination.Conclusions:Corticosteroids seem to be an effective treatment for Graves’ ophthalmopathy compared to other treatments currently available. Oral corticosteroids appear to have increased effect when given with radiotherapy. IVCSs, with or without radiotherapy, seem to have the best documented efficacy. Side effects can also be overcome by the use of IVCS pulse therapy (without OCS), which needs to be pursued in further, separate research as an alternative to oral therapy, since it could be both more effective and safer.
Keywords: Administration, Oral, Adrenal Cortex Hormones - therapeutic use, Cohort Studies, Graves Disease - drug therapy, Graves Disease - radiotherapy, Radiotherapy, Random Allocation, Risk, Risk Factors
Editorial
01 January 2025 : Editorial
Editorial: The Human Cell Atlas. What Is It and Where Could It Take Us?DOI: 10.12659/MSM.947707
Med Sci Monit 2025; 31:e947707
In Press
Clinical Research
Cost-Effective Day Surgery for Arteriovenous Fistula Stenosis: A Viable Model for Hemodialysis PatientsMed Sci Monit In Press; DOI: 10.12659/MSM.946128
Clinical Research
Impact of Periodontal Treatment on Early Rheumatoid Arthritis and the Role of Porphyromonas gingivalis Anti...Med Sci Monit In Press; DOI: 10.12659/MSM.947146
Clinical Research
C-Reactive Protein, Uric Acid, and Coronary Artery Ectasia in Patients with Coronary Artery DiseaseMed Sci Monit In Press; DOI: 10.12659/MSM.947158
Clinical Research
Effects of Remote Exercise on Physical Function in Pre-Frail Older Adults: A Randomized Controlled TrialMed Sci Monit In Press; DOI: 10.12659/MSM.947105
Most Viewed Current Articles
17 Jan 2024 : Review article 6,964,204
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research 700,526
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Mar 2024 : Editorial 24,009
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and ...DOI :10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
28 Jan 2024 : Review article 18,806
A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and FutureDOI :10.12659/MSM.943912
Med Sci Monit 2024; 30:e943912